Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of JNJ-3989 + JNJ-6379 + nucleos(t)ide analog versus nucleos(t)ide analog alone in HBeAg-negative virologically suppressed chronic hepatitis B
2019-002674-31Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2019
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tomligisiran, cetrelimab, entecavir, tenofovir disoproxil fumarate and tenofovir alafenamide in Chronic Hepatitis B (CHB) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: HBsAg seroclearance at Week 72 without restarting nucleos(t)ide analog treatment. Started Oct 2019; status: completed.
02
Drugs
tomligisirancetrelimabentecavirtenofovir disoproxil fumaratetenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2019-002674-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002674-31.